Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS Active Biotech, 23 Apr 2015 Accessed on 28 Apr 2015 from http://activebiotech.com/press-releases-1?pressid=1913972. CommentRecommendBookmarkWatch